G protein-coupled receptors

TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)

Retrieved on: 
Monday, November 9, 2020

Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn in S. Korea and Burixafor worldwide.

Key Points: 
  • Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn in S. Korea and Burixafor worldwide.
  • Apart from upfront fees, TaiGen will receive shares of GPCR Therapeutics as well as future milestone and royalty payments.
  • CXCR4 antagonism is a well-accepted avenue towards cancer therapy and GPCR Therapeutics is well experienced and possesses the necessary know-how to develop Burixafor in the oncology field.
  • Based in Seoul, S. Korea, GPCR Therapeutics is a biopharmaceutical company developing drugs based on the novel science of GPCR (G Protein-Coupled Receptor) heteromers.

New Comprehensive CBD Alternative from Life Extension®, Introducing Endocannabinoid Support, without THC or Hemp

Retrieved on: 
Tuesday, October 13, 2020

The relationship between these endocannabinoids and their specialized cellular receptors is shape-specificlike puzzle pieces, said Dr. Michael Smith, Life Extensions Director of Education.

Key Points: 
  • The relationship between these endocannabinoids and their specialized cellular receptors is shape-specificlike puzzle pieces, said Dr. Michael Smith, Life Extensions Director of Education.
  • According to Dr. Smith, it is not necessary to turn to CBD products to support your endocannabinoid system.
  • Weve also harnessed cannabimimeticsnutrients that that interact with the endocannabinoid systemto encourage healthy activity of endocannabinoid compounds, endocannabinoid receptors and the enzymes that control your endocannabinoid system.
  • By targeting endocannabinoid receptors, inhibiting the enzymes that break down endocannabinoid compounds and encouraging youthful circulating levels of endocannabinoids, weve found a great way to support your endocannabinoid system, Dr. Smith added.

Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy

Retrieved on: 
Monday, October 5, 2020

RBD selectively accumulates in the lysosomes of cancer cells upon contact, disrupts these lysosomes, and causes the cells to die.

Key Points: 
  • RBD selectively accumulates in the lysosomes of cancer cells upon contact, disrupts these lysosomes, and causes the cells to die.
  • Secondary endpoints include objective response rate (ORR) of injected target and measurable bystander lesions, target lesion somatostatin receptor expression, and biochemical response.
  • Disease response assessments are conducted by independent review using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
  • Six patients in the first cohort each received one percutaneously-administered injection of PV-10 to one target lesion per treatment cycle.

Following a Delayed Launch, Bristol Myers Squibb's Zeposia has Begun to Successfully Establish Itself as a Low-Burden Option Within the S1P Receptor Modulator Class, According to Spherix Global Insights

Retrieved on: 
Wednesday, September 16, 2020

As the third-to-market S1P receptor modulator, Zeposia shows early signs of promise in MS.

Key Points: 
  • As the third-to-market S1P receptor modulator, Zeposia shows early signs of promise in MS.
  • Neurologists project Zeposia share to rival that of Mayzent within the next six months.
  • Already, more physicians prefer Zeposia than Mayzent among the oral DMTs, although Novartis' Gilenya is still the most preferred S1P receptor modulator DMT.
  • Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence.

Surrozen to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 16, 2020

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will participate in a fireside chat at the Morgan Stanley 18th Annual Healthcare Conference.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will participate in a fireside chat at the Morgan Stanley 18th Annual Healthcare Conference.
  • Since its founding in 2016, Surrozen has developed two proprietary platforms to selectively modulate the Wnt pathway for the potential treatment of injury and disease.
  • Surrozen R-spondin-mimetics, also referred to as SWEETS (SurrozenWnt signal enhancers engineered fortissuespecificity), are antibody-based molecules that enhance Wnt signaling by stabilizing Frizzled receptorson targeted cells.
  • Investors/Partners/Media: Reza Afkhami VP, Corporate Development and Strategy Surrozen, Inc. [email protected]

RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.

Retrieved on: 
Tuesday, September 8, 2020

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

Key Points: 
  • Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
  • The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors.
  • A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
  • Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.

Retrieved on: 
Tuesday, September 8, 2020

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

Key Points: 
  • Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
  • The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors.
  • A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
  • Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH

Retrieved on: 
Tuesday, September 1, 2020

GAITHERSBURG, Md., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the successful completion of multiple dose toxicity and toxicokinetic studies of ALT-801, a GLP-1/glucagon dual receptor agonist for the treatment of NASH.

Key Points: 
  • GAITHERSBURG, Md., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the successful completion of multiple dose toxicity and toxicokinetic studies of ALT-801, a GLP-1/glucagon dual receptor agonist for the treatment of NASH.
  • The most remarkable finding was significant weight loss versus the control groups in both species, which is an expected and desired property of ALT-801.
  • Importantly, no evidence of significant GI toxicity or intolerability, including vomiting, was observed in the animals.
  • ALT-801 demonstrated better outcome measures in comparison to semaglutide (an approved GLP-1 receptor agonist) in the Gubra/Amylin biopsy-proven, diet-induced mouse model of NASH.

Chemist Develops Potential Drug to Treat Type 2 Diabetes Without Harsh Side Effects

Retrieved on: 
Monday, August 31, 2020

This drug could therefore benefit diabetes patients who also live with cystic fibrosis, COPD, sarcopenia, cancer, or HIV, where weight-loss is counter-indicated.

Key Points: 
  • This drug could therefore benefit diabetes patients who also live with cystic fibrosis, COPD, sarcopenia, cancer, or HIV, where weight-loss is counter-indicated.
  • The next step in the development of this groundbreaking drug is to move it through the pre-clinical phase into phase I human studies.
  • So, my group is pushing to expand on GLP-1R agonists to treat diabetes with obesity (DoD project) and then separately to treat diabetes without affecting nutritional status (corrination).
  • A common group of drugs used to treat type 2 diabetes are glucagon-like peptide-1 receptor (GLP-1R) agonists.

Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference

Retrieved on: 
Thursday, August 6, 2020

A live audio webcast of the presentation will be available under Events & Presentations in the Investor Relations section of the Companys website at www.rhythmtx.com .

Key Points: 
  • A live audio webcast of the presentation will be available under Events & Presentations in the Investor Relations section of the Companys website at www.rhythmtx.com .
  • A replay of the webcast will be available on the Rhythm website for 30 days following each presentation.
  • Rhythm is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity.
  • The Company is developing setmelanotide, its investigational, melanocortin-4 receptor (MC4R) agonist, for the treatment of severe obesity and hyperphagia associated with rare genetic disorders of obesity.